DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lc7znz/depression) has announced the addition of the "Depression Pipeline Highlights - 2015" report to their offering.
The latest report Depression Pipeline Highlights - 2015, provides most up-to-date information on key pipeline molecules in the global Depression market. It covers emerging therapies for Depression in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Depression pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Depression pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Depression pipeline molecules by the Originator Company.
Short-term Launch Highlights:
Find out which Depression pipeline products will be launched in the US and Ex-US till 2017.
Key Topics Covered:
1. Depression Pipeline by Stages
2. Depression Pipeline by Drug Class
3. Depression Pipeline by Company
4. Depression Phase 3 Clinical Trial Insights
5. Depression Phase 2 Clinical Trial Insights
6. Depression Phase 1 Clinical Trial Insights
7. Depression Preclinical Research Insights
8. Depression Discovery Stage Insights
10. Research Methodology
For more information visit http://www.researchandmarkets.com/research/lc7znz/depression